T. Rowe Price Associates
HRMY icon

T. Rowe Price Associates’s Harmony Biosciences HRMY Stock Holding History

T. Rowe Price Associates’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.34M Buy
47,714
+6,255
+15% +$205K ﹤0.01% 1999
2025
Q4 		$1.55M Buy
41,459
+5,011
+14% +$165K ﹤0.01% 1874
2025
Q3 		$1M Buy
36,448
+1,616
+5% +$55.7K ﹤0.01% 2066
2025
Q2 		$1.1M Buy
34,832
+4,993
+17% +$161K ﹤0.01% 1948
2025
Q1 		$991K Buy
29,839
+10,051
+51% +$360K ﹤0.01% 1963
2024
Q4 		$681K Buy
19,788
+4,911
+33% +$169K ﹤0.01% 2148
2024
Q3 		$596K Buy
14,877
+185
+1% +$6.5K ﹤0.01% 2182
2024
Q2 		$444K Buy
14,692
+473
+3% +$14.2K ﹤0.01% 2235
2024
Q1 		$478K Buy
14,219
+1,201
+9% +$38.5K ﹤0.01% 2230
2023
Q4 		$421K Buy
13,018
+620
+5% +$17.3K ﹤0.01% 2252
2023
Q3 		$407K Buy
12,398
+717
+6% +$24.9K ﹤0.01% 2211
2023
Q2 		$412K Buy
11,681
+1,628
+16% +$56.2K ﹤0.01% 2222
2023
Q1 		$329K Buy
10,053
+454
+5% +$20.7K ﹤0.01% 2299
2022
Q4 		$529K Buy
9,599
+357
+4% +$19.6K ﹤0.01% 2104
2022
Q3 		$410K Buy
9,242
+1,740
+23% +$84.9K ﹤0.01% 2228
2022
Q2 		$366K Buy
7,502
+437
+6% +$19.7K ﹤0.01% 2358
2022
Q1 		$344K Buy
7,065
+500
+8% +$20.4K ﹤0.01% 2492
2021
Q4 		$280K Buy
+6,565
New +$262K ﹤0.01% 2613
2020
Q4 		– Sell
-209,361
Closed -$7.1M – 2696
2020
Q3 		$7.1M Buy
+209,361
New +$7.63M ﹤0.01% 1363

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

T. Rowe Price Associates's HRMY Position: Q1 2026 in Review

T. Rowe Price Associates increased its Harmony Biosciences (HRMY) stake by 15% in Q1 2026, buying an estimated $205K and bringing the position to 47,714 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #1999.

T. Rowe Price Associates first reported a position in HRMY in Q3 2020 and has held it in 19 quarters since. The position peaked at $7.1M in Q3 2020. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • T. Rowe Price Associates held 47,714 shares of Harmony Biosciences worth $1.34M as of Q1 2026.
  • T. Rowe Price Associates bought 6,255 Harmony Biosciences shares in Q1 2026, an estimated $205K.
  • Harmony Biosciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1999 holding.
  • T. Rowe Price Associates first reported a position in Harmony Biosciences in Q3 2020 and has held it in 19 quarters since.
  • T. Rowe Price Associates's Harmony Biosciences position peaked at $7.1M in Q3 2020.
  • 309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.